<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Epidemiology and risk factors of urothelial (transitional cell) carcinoma of the bladder</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Epidemiology and risk factors of urothelial (transitional cell) carcinoma of the bladder</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Epidemiology and risk factors of urothelial (transitional cell) carcinoma of the bladder</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Siamak Daneshmand, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Joaquim Bellmunt, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sonali M Shah, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 29, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Bladder cancer is the most common malignancy involving the urinary system and the ninth most common malignancy worldwide [<a href="#rid1">1</a>]. Urothelial (previously known as transitional cell [TCC]) carcinoma is the predominant histologic type in the United States and Western Europe, where it accounts for approximately 90 percent of bladder cancers. In other areas of the world, such as the Middle East, both urothelial and non-urothelial histologies are seen, with the latter due at least in part to the prevalence of schistosomiasis [<a href="#rid2">2</a>]. (See  <a class="medical medical_review" href="/z/d/html/2964.html" rel="external">"Non-urothelial bladder cancer", section on 'Schistosomal bladder cancer'</a>.)</p><p>Studies of urothelial bladder cancer have identified multiple risk factors, the most important of which are cigarette smoking and various occupational exposures. Numerous other factors have also been identified that may play an etiologic role in some cases of urothelial cancer, although interpretation of the evidence is frequently confounded by exposure to tobacco use.</p><p>The epidemiology and risk factors associated with urothelial cancer of the bladder will be reviewed here. Non-urothelial bladder cancer is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2964.html" rel="external">"Non-urothelial bladder cancer"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY</span></p><p class="headingAnchor" id="H3"><span class="h2">Incidence and prevalence</span><span class="headingEndMark"> — </span>Bladder cancer is one of the most common cancers in the world. Globally, there were approximately 570,000 new cases and over 210,000 deaths due to bladder cancer in 2020 [<a href="#rid3">3</a>]. In the United States, approximately 83,000 new cases and 17,000 deaths occur each year due to bladder cancer [<a href="#rid4">4</a>]. In Europe, there were an estimated 118,000 cases and 52,000 deaths in 2012 [<a href="#rid5">5</a>]. In developed regions such as North America and Europe, bladder cancer is predominantly urothelial.</p><p>Since the 1970s, the five-year survival rate for those diagnosed with bladder cancer in the United States has improved to approximately 80 percent [<a href="#rid4">4</a>]. Mortality rates in several western European countries have shown similar downward trends but are still increasing in some eastern European countries [<a href="#rid6">6</a>].</p><p>Many bladder cancer patients do not die of their disease but do experience multiple recurrences. As a consequence, there are a relatively large number of people alive with a history of bladder cancer. In middle-aged and older adult males, bladder cancer is the second most prevalent malignancy after prostate cancer [<a href="#rid7">7,8</a>].</p><p class="headingAnchor" id="H4"><span class="h2">Geographic distribution</span><span class="headingEndMark"> — </span>Geographically, there is a wide variation in the incidence of urothelial cancer of the bladder, with Western Europe and North America having the highest incidence and Eastern Europe and Asian countries having the lowest rates [<a href="#rid6">6,9</a>]. Even within the United States, there are substantial regional differences in the incidence of bladder cancer between states [<a href="#rid4">4</a>]. These differences are only slightly attenuated after controlling for smoking [<a href="#rid10">10</a>].</p><p class="headingAnchor" id="H5"><span class="h2">Age, sex, and race</span><span class="headingEndMark"> — </span>Bladder cancer is typically diagnosed in older individuals. A majority (approximately 73 percent) of patients with bladder cancer are older than 65 years of age [<a href="#rid11">11</a>]. The median age at diagnosis is 69 years in males and 71 years in females [<a href="#rid12">12,13</a>]. The incidence increases with age from 142 to 296 per 100,000 in males aged 65 to 69 years and 85 and over, respectively, and from 33 to 74 per 100,000 in females in the same age groups. The age of onset is younger in current smokers than in never smokers [<a href="#rid14">14</a>]. The relative risk for current versus never cigarette smokers is the same in males and females (4.0 and 4.7, respectively), reflecting converging smoking patterns [<a href="#rid15">15</a>]. (See <a class="local">'Cigarette smoke'</a> below.)</p><p>Although extremely rare, bladder cancer can be seen in children and young adults, where it usually presents with low-grade, noninvasive disease [<a href="#rid16">16</a>].</p><p>There are racial and ethnic variations in bladder cancer incidence. In the United States, White males have the highest risk with roughly twice the incidence seen in African American and Hispanic males [<a href="#rid17">17</a>]. Postulated explanations for these racial and ethnic differences include variations in acetylator phenotypes among different racial/ethnic groups and occupational differences among underrepresented groups that influence exposure to industrial carcinogens [<a href="#rid18">18</a>]. (See <a class="local">'Occupational carcinogen exposure'</a> below and <a class="local">'Detoxification of carcinogens'</a> below.)</p><p>In addition to differences in incidence, sex and race also affect the stage at presentation and prognosis. Although the overall incidence of bladder cancer is lower in females and African Americans, these groups have more advanced-stage tumors at presentation compared with White males [<a href="#rid13">13</a>].</p><p class="headingAnchor" id="H6"><span class="h1">RISK FACTORS</span><span class="headingEndMark"> — </span>Environmental exposures account for most cases of bladder cancer. The surface epithelium (urothelium) that lines the mucosal surfaces of the entire urinary tract is exposed to potential carcinogens that are either excreted in the urine or activated from precursors in the urine by hydrolyzing enzymes. This "field cancerization" effect is one hypothesis to explain the multifocal occurrence that is a characteristic feature of urothelial carcinomas of both the urinary bladder and the upper urinary tract [<a href="#rid19">19-22</a>].</p><p>However, in the majority of cases, multifocal urothelial carcinomas are monoclonal [<a href="#rid21">21,23-25</a>]. This supports their presumed origin from a single genetically altered cell, which then spreads through the urothelium via intraluminal seeding or intraepithelial migration. This is referred to as the monoclonality hypothesis.</p><p>Although the monoclonality hypothesis appears to conflict with field cancerization, both mechanisms are probably operative in urothelial carcinogenesis, as has been shown with squamous carcinogenesis in the oral cavity. (See  <a class="medical medical_review" href="/z/d/html/3390.html" rel="external">"Epidemiology and risk factors for head and neck cancer"</a>.)</p><p class="headingAnchor" id="H7"><span class="h1">ENVIRONMENTAL FACTORS</span></p><p class="headingAnchor" id="H8"><span class="h2">Chemical carcinogenesis</span><span class="headingEndMark"> — </span>Chemical carcinogenesis is believed to be responsible for much of the burden of bladder cancer, including the increased risk associated with cigarette smoke as well as various industrial exposures. The relationship of bladder cancer to chemical carcinogens was initially suggested by the high incidence of bladder cancer in workers with particular chemical exposures. (See <a class="local">'Occupational carcinogen exposure'</a> below.)</p><p>Subsequent epidemiologic and laboratory studies have identified a large number of chemical compounds thought to be carcinogenic. Most are aromatic amines, such as 2-naphthylamine, benzidine, and their precursors or derivatives. Other well-characterized carcinogenic chemicals include 4-aminobiphenyl, 4-nitrobiphenyl, and 2-amino-1-naphthol [<a href="#rid26">26-28</a>]. The long latent period between exposure and the development of urothelial carcinoma, combined with exposures to multiple compounds, has complicated studies attempting to identify specific carcinogens.</p><p class="headingAnchor" id="H9"><span class="h3">Cigarette smoke</span><span class="headingEndMark"> — </span>Cigarette smoking is the most important factor contributing to the overall incidence of urothelial cancer in western countries [<a href="#rid29">29-31</a>]. The carcinogenic compounds present in cigarettes that are responsible for bladder cancer have not been definitively identified. There are over 60 known carcinogens and reactive oxygen species present, including 4-aminobiphenyl (4-ABP), polycyclic aromatic hydrocarbons, N-nitroso compounds, and unsaturated aldehydes [<a href="#rid32">32,33</a>].</p><p>The relationship between cigarette smoking and the risk of bladder cancer is illustrated by a prospective analysis in the National Institutes of Health-AARP Diet and Health Study Cohort [<a href="#rid29">29</a>]. This database included over 465,000 individuals followed from 1995 to 2006 in the United States. For current smokers, there was a significant increase in the risk of bladder cancer for both males and females (multivariate adjusted hazard ratios [HRs] 3.89 and 4.65, respectively). Although there was an attenuation of risk in former smokers, the risk remained significantly elevated (HRs 2.14 and 2.52 for males and females, respectively). There was a small but statistically significant increase in the incidence of bladder cancer among males who smoked a pipe or cigars but not cigarettes (HR 1.29).</p><p>In this analysis, the population attributable risk was 50 and 52 percent for males and females, respectively [<a href="#rid29">29</a>]. Compared with prospective cohort studies from earlier time periods [<a href="#rid34">34,35</a>], the percentage of cases attributable to cigarette smoking has remained constant in males despite a decrease in the overall incidence of smoking, while the percentage has increased in females, presumably reflecting the increase in cigarette smoking among females [<a href="#rid29">29</a>]. Increases in the content of specific carcinogens such as beta naphthylamine in cigarettes were postulated as contributing to these changes.</p><p>The extent of cigarette smoking appears to be related to the aggressiveness of bladder cancer. In a study of 740 patients diagnosed over a 22 year period, heavy smokers (≥30 pack years) were more likely to have a high-grade tumor and to have muscle-invasive disease at their original presentation compared with nonsmokers [<a href="#rid36">36</a>]. Additionally, patients who continue to smoke at the time of treatment for bladder cancer also can experience worsened clinical outcomes, such as increased risk of recurrent disease, decreased response to chemotherapy, and higher mortality rates [<a href="#rid37">37</a>].</p><p class="headingAnchor" id="H10"><span class="h4">Smoking cessation</span><span class="headingEndMark"> — </span>Smoking cessation decreases but does not eliminate the increased risk of bladder cancer [<a href="#rid29">29,30</a>]. </p><p>A meta-analysis that included data from 88 studies found that the relative risks of bladder cancer for all smokers, current smokers, and former smokers compared with nonsmokers were 2.62 (95% CI 2.43-2.83), 3.49 (3.13-3.88), and 2.07 (1.84-2.33), respectively [<a href="#rid30">30</a>]. Smoking cessation also appears to decrease the recurrence rate for patients with non-muscle-invasive bladder cancer even after the diagnosis [<a href="#rid38">38</a>].</p><p>Approaches to smoking cessation are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/16634.html" rel="external">"Overview of smoking cessation management in adults"</a>.)</p><p class="headingAnchor" id="H11"><span class="h4">Secondhand smoke</span><span class="headingEndMark"> — </span>Exposure to secondhand cigarette smoke in females appears to be a risk factor for the development of bladder cancer [<a href="#rid39">39,40</a>].</p><p>The role of secondhand smoke was illustrated by a study from Los Angeles County that included 148 individuals with bladder cancer and 292 controls, all of whom were never smokers [<a href="#rid40">40</a>]. Females who lived with two or more smokers during childhood had a threefold increased risk of bladder cancer compared with those without a childhood exposure to secondhand smoke, while females with a domestic partner who smoked for 10 or more years had a twofold increased risk compared with those without such exposure. These associations were not observed in male never smokers.</p><p>Levels of environmental carcinogens were compared in those with exposure to secondhand smoke by directly quantifying 4-aminobiphenyl (4-ABP) hemoglobin adducts, which are established biomarkers of 4-ABP exposure [<a href="#rid40">40</a>]. Mean levels of 4-ABP adducts were highest in females with current exposure to environmental smoke and lowest in those with no history of exposure.</p><p class="headingAnchor" id="H1882818818"><span class="h3">Is cannabis smoke a risk factor?</span><span class="headingEndMark"> — </span>Cannabis smoke, however, has not been found to be a risk factor for bladder cancer [<a href="#rid23">23,41</a>]. Further details on the association between cannabis smoke and cancer are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7797.html" rel="external">"Cannabis use and disorder: Epidemiology, pharmacology, comorbidities, and adverse effects", section on 'Medical and systemic effects'</a>.)</p><p class="headingAnchor" id="H61137307"><span class="h3">Opium</span><span class="headingEndMark"> — </span>The use of opium has been associated with an increased risk of bladder cancer, and it is considered carcinogenic to humans by the International Agency on Research for Cancer (IARC) [<a href="#rid42">42,43</a>]. Opium is an illicit substance derived from the poppy plant, specifically from the juice of the unripe seedpod. Opium contains multiple alkaloids and is considered carcinogenic to humans when smoked or ingested in various forms (eg, raw, dross, or sap opium). </p><p>Observational data consistently support an association between opium use and bladder cancer [<a href="#rid43">43,44</a>]. As an example, in one meta-analysis that included data from five case-control studies, the odds ratio for developing bladder cancer with opium but not tobacco use was 3.4 (95% CI 1.6-7.2) [<a href="#rid44">44</a>]. Of note, these data do not include other opiates such as heroin, <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">morphine</a>, <a class="drug drug_general" data-topicid="9291" href="/z/d/drug information/9291.html" rel="external">codeine</a>, or <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">fentanyl</a>.</p><p class="headingAnchor" id="H12"><span class="h4">Occupational carcinogen exposure</span><span class="headingEndMark"> — </span>The relationship between workplace exposure to various chemical carcinogens and an increased risk of urothelial cancer was first noted over a century ago. Such exposures are thought to account for approximately 10 to 20 percent of bladder cancers [<a href="#rid45">45,46</a>]. For workers with substantial industrial exposure, the risk may be elevated as much as 200-fold compared with matched controls without such chemical carcinogen exposure [<a href="#rid47">47</a>]. The risk of death from bladder cancer appears to be elevated for more than 30 years after cessation of exposure to occupational carcinogens [<a href="#rid48">48</a>].</p><p>Occupations that have been linked to an increased risk of bladder cancer include metal workers, painters, rubber industry workers, leather workers, textile and electrical workers, miners, cement workers, transport operators, excavating-machine operators, and jobs that involve manufacture of carpets, paints, plastics, and industrial chemicals [<a href="#rid26">26,49,50</a>].</p><p>Bladder cancer also has been associated with exposure to paint components, polycyclic aromatic hydrocarbons (PAHs), and diesel exhausts [<a href="#rid50">50,51</a>]. In a cohort study that included more than 58,000 males in the Netherlands, investigators found only "marginal" evidence for increased risk of bladder cancer due to diesel exhaust, although this risk was more pronounced in current smokers [<a href="#rid51">51</a>]. In a meta-analysis of 35 studies reviewing occupational exposure to diesel exhaust, the summary relative risk (RR) of developing bladder cancer was 1.13 (95% CI 1-1.27) with a positive dose response relation (RR 1.44 for high diesel exposure) [<a href="#rid52">52</a>].</p><p>Firefighters are exposed to a variety of potential chemical carcinogens at the scene of a fire and its aftermath as well as at the firehouse. Potential carcinogenic compounds include benzene, polyaromatic hydrocarbons, and diesel exhausts, among others. Although some individual studies found a modest increase in the risk of developing bladder cancer among firefighters [<a href="#rid51">51,53,54</a>], two meta-analyses could not identify clear evidence that employment as a firefighter was associated with an increased risk of bladder cancer [<a href="#rid55">55,56</a>].</p><p>Carcinogenic compounds have also been identified in hair dyes [<a href="#rid57">57</a>]. Numerous epidemiologic studies have investigated the relationship between occupational exposure to hair dye use and the risk of bladder cancer [<a href="#rid58">58-62</a>]. As an example, a fivefold increase in risk of bladder cancer was observed in subjects who worked for 10 or more years as hairdressers or barbers in a population-based case-control study of 1514 incident cases of bladder cancer in Los Angeles [<a href="#rid62">62</a>]. Changes in hair dye formulations and the widespread implementation of safety measures appear to have decreased this risk [<a href="#rid60">60</a>].</p><p>This increase in risk does not appear to extend to personal users of such hair dyes. (See <a class="local">'Other factors'</a> below.)</p><p class="headingAnchor" id="H13"><span class="h2">Drinking water</span></p><p class="headingAnchor" id="H14"><span class="h3">Chlorination</span><span class="headingEndMark"> — </span>Chlorination is the most common process by which drinking water is decontaminated for use by the general population. Trihalomethanes (THMs) are formed as a by-product when chlorine or bromine is used to disinfect water for drinking and may have adverse health effects at high concentrations. Many governments now set limits on the maximum level permissible in drinking water.</p><p>Several epidemiologic studies have investigated a possible relationship between chlorination of drinking water and the risk of bladder cancer [<a href="#rid63">63-65</a>]. As an example, one meta-analysis that included six case-control and two cohort studies with more than 6000 bladder cancer cases and 10,000 controls in total showed that long-term consumption of chlorinated drinking water was associated with an increased risk of bladder cancer in males (odds ratio [OR] 1.4, 95% CI 1.1-1.9) and a nonsignificant increase in females (OR 1.2, 95% CI 0.7-1.8) [<a href="#rid63">63</a>].</p><p>Further evidence supporting this hypothesis comes from a study suggesting that ozonation decreases the concentration of THMs and reduces the risk of bladder cancer associated with the chlorination of drinking water [<a href="#rid66">66</a>].</p><p class="headingAnchor" id="H15"><span class="h3">Arsenic</span><span class="headingEndMark"> — </span>Multiple epidemiologic studies have established a link between high concentrations of arsenic in drinking water and the subsequent development of bladder cancer [<a href="#rid67">67-69</a>]. This relationship has been most clearly defined in areas of Chile and Taiwan, where subsequent removal of arsenic from drinking water sources led to a decline in the incidence of bladder cancer [<a href="#rid68">68,69</a>]. Although the precise mechanism by which arsenic induces bladder cancer is unknown, it probably acts by causing chromosomal alterations [<a href="#rid70">70</a>].</p><p>The association between arsenic and bladder cancer is influenced by the level of arsenic in drinking water. Data from Taiwan indicate that bladder cancer cases in high arsenic areas are associated with more aggressive disease and a poorer prognosis [<a href="#rid71">71</a>]. However, multivariate analysis suggested that the prognosis was similar when corrected for stage and grade. Other studies have also shown that low-level arsenic exposure alone did not appear to be a significant independent risk factor for bladder cancer, although the data remain uncertain [<a href="#rid72">72</a>].</p><p>The relationship of arsenic in drinking water to bladder cancer and other malignancies is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2778.html" rel="external">"Arsenic exposure and chronic poisoning", section on 'Cancer'</a>.)</p><p class="headingAnchor" id="H16"><span class="h3">Fluid intake</span><span class="headingEndMark"> — </span>An increase in total fluid intake may dilute excreted urinary carcinogens and reduce contact time with the urothelium. In the Health Professional Follow-up Study involving almost 48,000 participants over a period of 10 years, multivariate analysis found that total daily fluid intake was inversely associated with the risk of bladder cancer (RR 0.51, 95% CI 0.32-0.80 for daily fluid intake &gt;2.5 L per day compared with &lt;1.3 L per day) [<a href="#rid73">73</a>].</p><p>Additional evidence supporting a relationship between the extent of urothelial exposure to potential carcinogens and the risk of bladder cancer comes from a case-control study of 884 individuals with bladder cancer and 996 controls [<a href="#rid74">74</a>]. An increased frequency of urination, particularly nocturia, was associated with a significantly decreased risk of bladder cancer. Other epidemiologic studies, however, have not confirmed this association [<a href="#rid6">6</a>].</p><p class="headingAnchor" id="H17"><span class="h2">Aristolochic acid</span><span class="headingEndMark"> — </span>Consumption of Chinese herbs that contain aristolochic acid or prescription of aristolochic acid has been associated with an increased incidence of urinary tract infections and urothelial malignancies of the bladder, ureter, and renal pelvis [<a href="#rid75">75</a>]. (See  <a class="medical medical_review" href="/z/d/html/7206.html" rel="external">"Nephropathy induced by aristolochic acid (AA) containing herbs", section on 'Pathogenesis'</a>.)</p><p class="headingAnchor" id="H18"><span class="h2">Chemoprevention</span><span class="headingEndMark"> — </span>The recognition that environmental factors are responsible for most cases of lung cancer provides an opportunity to minimize the incidence of bladder cancer by blocking these changes. A variety of approaches are being studied, but none has been shown to effectively decrease the incidence of bladder cancer. Further data on chemoprevention of bladder and lung cancer incidence are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2971.html" rel="external">"Chemoprevention of urothelial carcinoma of the bladder"</a> and  <a class="medical medical_review" href="/z/d/html/4604.html" rel="external">"Chemoprevention of lung cancer"</a>.)</p><p class="headingAnchor" id="H19"><span class="h1">MISCELLANEOUS FACTORS</span></p><p class="headingAnchor" id="H20"><span class="h2">Chronic cystitis</span><span class="headingEndMark"> — </span>Individuals with recurrent or chronic bladder infections and those who have an ongoing source of bladder inflammation (eg, prolonged indwelling catheters in the setting of spinal cord injury, bladder calculi, gonorrhea, neurogenic bladder, spina bifida) have a higher risk of bladder cancer compared with the general population [<a href="#rid76">76-79</a>]. In this setting, there is a substantially higher incidence of non-urothelial cancers, especially squamous cell carcinoma. (See  <a class="medical medical_review" href="/z/d/html/2964.html" rel="external">"Non-urothelial bladder cancer"</a>.)</p><p>Chronic urinary tract infections are thought to contribute to bladder carcinogenesis by several mechanisms:</p><p class="bulletIndent1"><span class="glyph">●</span>Repeated chronic irritation can lead to metaplastic changes, then dysplasia, and finally carcinoma.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Chronic infection predisposes to obstructive uropathy, bacterial superinfection, and the production of nitrosamines in the acidic urine environment. Nitrosamines are capable of inducing bladder cancer in animal models [<a href="#rid80">80,81</a>]. In addition, the bacteria themselves are capable of activating N-nitroso compounds to nitric oxide radicals, which can produce oxidative damage to tissues and DNA.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Inflammatory cells, including neutrophils, eosinophils, and macrophages, are also rich sources of reactive oxygen species that are produced by endogenous enzymatic reactions. Local infiltration of these cells into the bladder mucosa provides angiogenic and lymphangiogenic growth factors, cytokines, and proteases, all of which may enhance tumor progression [<a href="#rid82">82</a>]. In addition, the proinflammatory signals that target the elimination of infection in the acute phase subsequently switch their function from the killing of the intruder to tissue healing, thereby providing further growth opportunities for incipient tumors [<a href="#rid83">83,84</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Genetic variations in the genes involved in the inflammatory response (eg, single-nucleotide polymorphisms in the interleukin-6 gene [<a href="#rid85">85</a>]) may alter their expression and function, potentially affecting the risk of developing bladder cancer in the setting of chronic inflammation.</p><p></p><p class="headingAnchor" id="H368026843"><span class="h2">Human papillomavirus infection</span><span class="headingEndMark"> — </span>Multiple studies have suggested that there is a relationship between human papillomavirus (HPV) infection and urothelial bladder cancer [<a href="#rid86">86</a>]. A meta-analysis that included data from 52 studies and 2855 cases of bladder cancer found that the prevalence of HPV was 17 percent [<a href="#rid87">87</a>]. Most of these were associated with high-risk serotypes of HPV, especially HPV 16.</p><p class="headingAnchor" id="H21"><span class="h2">Upper urinary tract cancer</span><span class="headingEndMark"> — </span>Urothelial cancers of the renal pelvis and ureter are thought to be due to the same etiologic factors as urothelial cancer of the bladder. Thus, it is not surprising that patients with urothelial cancer of the upper urinary tract are at high risk for the subsequent development of urothelial cancer of the urinary bladder as well as contralateral upper urinary tract malignancy [<a href="#rid88">88,89</a>].</p><p>The magnitude of this effect was illustrated by a series of 82 patients who had complete resection of a urothelial cancer of the renal pelvis or ureter. In this series, urothelial carcinoma of the bladder was subsequently diagnosed in 36 (44 percent) at a median interval of 14 months [<a href="#rid88">88</a>]. The bladder tumors were frequently multifocal (mean 2.1 per patient). (See  <a class="medical medical_review" href="/z/d/html/2987.html" rel="external">"Malignancies of the renal pelvis and ureter"</a>.)</p><p>The role of various risk factors for bladder recurrence or contralateral upper tract recurrence was illustrated in a series of 223 patients with documented primary upper urinary tract urothelial carcinoma, who had been managed definitively by either complete surgical extirpation or endoscopic resection [<a href="#rid20">20</a>]. Recurrent bladder tumors and contralateral upper urinary tract tumors were identified in 31 and 6 percent, respectively. Multiplicity of the initial upper urinary tract tumor was a risk factor for recurrence in the bladder.</p><p>The high frequency of bladder cancer in patients with urothelial cancer of the upper urinary tract requires that patients who have received definitive therapy for upper urinary tract urothelial cancer undergo close surveillance for primary tumors arising in the bladder as well as the contralateral upper urinary tract.</p><p>Tumor implantation into the bladder after radical nephroureterectomy is also a known risk factor for the development of bladder cancer due to drop metastases. Patients who undergo radical nephroureterectomy can be treated with a single postoperative dose of intravesical chemotherapy, which reduces the risk of secondary bladder tumors. (See  <a class="medical medical_review" href="/z/d/html/2987.html" rel="external">"Malignancies of the renal pelvis and ureter", section on 'Drop metastases'</a> and  <a class="medical medical_review" href="/z/d/html/2987.html" rel="external">"Malignancies of the renal pelvis and ureter", section on 'Postoperative intravesical chemotherapy'</a>.)</p><p class="headingAnchor" id="H22"><span class="h2">Bladder augmentation</span><span class="headingEndMark"> — </span>Augmentation cystoplasty is occasionally used to treat neurogenic bladder and may also be undertaken if the bladder does not develop to a sufficient size to allow for continence.</p><p>Patients who undergo a bladder augmentation procedure (including both ileocystoplasty and gastrocystoplasty) appear to be at increased risk for the subsequent development of urothelial cancer [<a href="#rid90">90-92</a>]. The cumulative risk is estimated to be approximately 1 percent, with a latent period of less than 20 years [<a href="#rid92">92</a>].</p><p>These cancers may arise in the residual bladder urothelium or in the intestinal mucosa of the augmented bladder. Tumors have included urothelial carcinomas, adenocarcinomas [<a href="#rid93">93</a>], and at least one case of signet cell carcinoma [<a href="#rid94">94</a>].</p><p>Because of this increased risk, patients who undergo bladder augmentation procedures require close long-term follow-up, including annual cystoscopy beginning 10 years after the bladder augmentation [<a href="#rid90">90</a>].</p><p class="headingAnchor" id="H23"><span class="h2">Iatrogenic</span></p><p class="headingAnchor" id="H24"><span class="h3">Radiation therapy</span><span class="headingEndMark"> — </span>Several studies have shown an increased risk of bladder cancer following pelvic radiation for rectal, cervical, prostate, and testicular cancers [<a href="#rid31">31,95,96</a>]. However, this relationship has not been observed in all studies, and the magnitude of the risk appears to be small [<a href="#rid97">97,98</a>]. (See  <a class="medical medical_review" href="/z/d/html/6946.html" rel="external">"External beam radiation therapy for localized prostate cancer", section on 'Secondary malignancies'</a> and  <a class="medical medical_review" href="/z/d/html/14230.html" rel="external">"Approach to the long-term survivor of colorectal cancer", section on 'Second malignancies'</a>.)</p><p>Patients with a history of prior pelvic radiation who do develop urothelial cancer appear to have more advanced tumors with poorer survival than age- and stage-matched controls [<a href="#rid99">99-103</a>].</p><p class="headingAnchor" id="H25"><span class="h3">Cyclophosphamide</span><span class="headingEndMark"> — </span>Patients treated with <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> have up to a ninefold increase in risk of developing bladder cancer, with a latency period that is generally less than 10 years [<a href="#rid104">104-106</a>]. The risk of bladder cancer in patients receiving cyclophosphamide as an antitumor or immunosuppressive agent is illustrated by the following examples:</p><p class="bulletIndent1"><span class="glyph">●</span>In a study of 145 patients receiving chronic <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> therapy for granulomatosis with polyangiitis (GPA) between 1967 and 1993, urothelial cancer of the bladder developed in seven (5 percent) at a median follow-up of 8.5 years [<a href="#rid105">105</a>]. Six of these patients had received cumulative doses exceeding 100 grams with a cumulative duration of cyclophosphamide therapy of 2.7 years; all had episodes of gross hematuria during cyclophosphamide treatment. The duration and extent of cyclophosphamide exposure is far greater than current regimens used in GPA. (See  <a class="medical medical_review" href="/z/d/html/3105.html" rel="external">"Granulomatosis with polyangiitis and microscopic polyangiitis: Induction and maintenance therapy", section on 'Cyclophosphamide-based regimen'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A series of more than 6000 two-year survivors of non-Hodgkin lymphoma found a 4.5-fold increased risk of bladder cancer following therapy with <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> [<a href="#rid104">104</a>]. The absolute risk depended upon the cumulative dose and was greatest in those receiving ≥50 grams of cyclophosphamide [<a href="#rid104">104</a>].</p><p></p><p>Acrolein, a urinary metabolite of <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>, is thought to be responsible for both hemorrhagic cystitis as well as bladder cancer [<a href="#rid107">107</a>]. The uroprotectant <a class="drug drug_general" data-topicid="9615" href="/z/d/drug information/9615.html" rel="external">mesna</a> inactivates urinary acrolein and can lower the subsequent risk of hemorrhagic cystitis as well as bladder cancer when used in conjunction with cyclophosphamide [<a href="#rid108">108</a>]. (See  <a class="medical medical_review" href="/z/d/html/2829.html" rel="external">"Chemotherapy and radiation-related hemorrhagic cystitis in cancer patients"</a>.)</p><p class="headingAnchor" id="H26"><span class="h3">Analgesics</span><span class="headingEndMark"> — </span>Phenacetin, an analgesic that was widely used until the third quarter of the 20th century, has been linked to an increased risk of urothelial carcinoma, particularly of the renal pelvis [<a href="#rid109">109,110</a>]. In the late 1980s, it was recognized as a carcinogen and removed from analgesic compounds in the United States and Europe and largely replaced by <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a>, which does not increase the bladder cancer risk.</p><p>A number of studies have documented a decrease in the risk of bladder cancer with regular use of any nonsteroidal antiinflammatory drug (NSAID) [<a href="#rid111">111</a>], with a meta-analysis suggesting that NSAIDs, excluding <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a>, are associated with a reduction in risk of bladder cancer, particularly for nonsmokers, suggesting a protective effect by inhibition of the inflammatory and proliferative response, although others have found no association [<a href="#rid112">112</a>].</p><p>The relationship between analgesics and urinary tract malignancy is discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/7177.html" rel="external">"Urinary tract malignancy and atherosclerotic disease in patients with chronic analgesic abuse", section on 'Urinary tract malignancy'</a> and  <a class="medical medical_review" href="/z/d/html/7176.html" rel="external">"Epidemiology and pathogenesis of analgesic-related chronic kidney disease"</a>.)</p><p class="headingAnchor" id="H185945766"><span class="h3">Thiazolidinediones</span><span class="headingEndMark"> — </span>Thiazolidinediones are oral hypoglycemic agents indicated in the treatment of diabetes mellitus. There is concern about increased risk of bladder cancer with <a class="drug drug_general" data-topicid="10216" href="/z/d/drug information/10216.html" rel="external">pioglitazone</a>. However, the association is controversial, and whether this represents a class effect is unclear. Different reports have given conflicting results, and these data are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/1757.html" rel="external">"Thiazolidinediones in the treatment of type 2 diabetes mellitus", section on 'Bladder cancer'</a>.)</p><p class="headingAnchor" id="H27"><span class="h2">Other factors</span><span class="headingEndMark"> — </span>A number of other factors have been postulated as risk factors for bladder cancer. The available evidence for these suggests that these factors either are not associated with causing urothelial cancer or the increased risk is relatively small.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Air pollution </strong>– Air pollution has been postulated to increase the risk of bladder cancer, but studies have given conflicting results. A case-control study from Spain found a 30 percent increased risk of bladder cancer in individuals who lived for more than 40 years in a city with a population &gt;100,000, presumably secondary to emissions of polycyclic aromatic hydrocarbons and diesel from industries near the residence [<a href="#rid113">113</a>]. Other studies have not documented an excess in cancers related to air pollution compared with the general population [<a href="#rid114">114</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Artificial sweeteners </strong>– Large doses of artificial sweeteners, including saccharin and cyclamates, induce bladder tumors in rats [<a href="#rid115">115</a>]. The extremely high levels of the compounds, the timing of exposure during the perinatal period, and the lack of reproducibility in primate studies make the relevance of these findings unclear. Multiple case-control studies failed to show a definitive association between saccharin use and bladder cancer risk [<a href="#rid116">116,117</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Coffee and tea </strong>– A possible association of coffee and tea consumption with bladder cancer has been studied in numerous epidemiologic investigations. Although caffeine is a potentially mutagenic substance in vitro, observational studies have been inconsistent and have failed to demonstrate a significant relationship between regular use of coffee and bladder cancer. As examples, a meta-analysis that included 34 case-control and three follow-up studies found that coffee consumption increased the risk of urinary tract cancer by approximately 20 percent, while tea consumption was not associated with an increased risk [<a href="#rid118">118</a>]. By contrast, other studies suggested that normal coffee consumption is unlikely to be associated with an increased risk of bladder cancer when adjusted for smoking, consumption of large amounts (7 to 10 cups a day) may cause a slightly increased risk [<a href="#rid119">119,120</a>]. Similarly, a pooled analysis of 12 cohort studies suggested that the association between coffee consumption and bladder cancer in male smokers is not causal but rather confounded by smoking status, as this association was absent in nonsmokers and females [<a href="#rid121">121</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hair dyes </strong>– Although exposure to chemical carcinogens in hair stylists has been linked to an increased risk of bladder cancer, one meta-analysis based upon 10 studies did not identify an increased risk of bladder cancer in personal users of permanent hair dyes [<a href="#rid122">122</a>]. Other observational studies have consistently supported these results [<a href="#rid123">123</a>]. (See <a class="local">'Occupational carcinogen exposure'</a> above.)</p><p></p><p class="headingAnchor" id="H28"><span class="h1">GENETIC EFFECTS</span><span class="headingEndMark"> — </span>Carcinogenesis within the urothelium is the result of complex interactions involving oncogenes, tumor suppressor genes, and amplification or overexpression of normal genes that encode for growth factors or their receptors. These genetic abnormalities may directly modify the risk of developing bladder cancer or alter its natural history, and such factors may act alone or in concert with extrinsic factors.</p><p>Alternatively, genetic factors may indirectly affect the risk of bladder cancer by activating carcinogen precursors or by detoxifying carcinogens.</p><p class="headingAnchor" id="H29"><span class="h2">Heredity</span><span class="headingEndMark"> — </span>Multiple epidemiologic studies have looked at the role of genetic factors as risk factors for the development of bladder cancer.</p><p>In most studies, there has been a small increase in risk in relatives of those with bladder cancer, and the risk appears to be greatest in those whose affected relatives were diagnosed before age 60 years [<a href="#rid124">124-126</a>]. Although the risk is increased in never smokers, there appears to be an interaction with smoking and a larger increase in risk has been observed in smokers [<a href="#rid125">125</a>].</p><p>The possible relationship of heredity to the development of bladder cancer is illustrated by the following examples:</p><p class="bulletIndent1"><span class="glyph">●</span>A case-control study from the MD Anderson Cancer Center analyzed 713 bladder cancer patients and 658 controls [<a href="#rid125">125</a>]. Probands who had smoked and who had a positive family history for bladder cancer had a fivefold increased risk of developing bladder cancer. In an associated analysis of families of this cohort, the risk of bladder cancer was increased nearly sevenfold in relatives of patients who had been diagnosed with bladder cancer between ages 40 and 65 years who had a history of smoking, compared with never smokers with a negative family history.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the Swedish Family History Cancer Database from 1958 to 1996, bladder cancer was identified in a parent-offspring pair in 65 families [<a href="#rid124">124</a>]. The risk of bladder cancer was elevated in offspring of parents with bladder cancer (standardized incidence ratios [SIRs] 1.35 and 2.29 in sons and daughters, respectively). The highest risk was observed in brothers of patients diagnosed before age 45 (SIR 7.3), suggesting an X-linked inheritance.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The Spanish Bladder Cancer Study analyzed 1158 patients with newly diagnosed bladder cancer and 1244 controls [<a href="#rid127">127</a>]. There was a nonsignificant increase in the risk of bladder cancer in patients with a positive family history (odds ratio [OR] 2.34, 95% CI 0.95-5.77). An interaction with extrinsic factors was suggested by the observation that the risk was significantly increased in slow N-acetyltransferase-2 (NAT2) acetylators (OR 4.76, 95% CI 1.25-18.09) but not rapid or intermediate NAT-2 acetylators (OR 1.17, 95% CI 0.17-7.86) [<a href="#rid127">127</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Another observational analysis of 586 patients with urothelial carcinoma showed that traditional family history-based criteria may not identify all patients with hereditary urothelial cancer susceptibility [<a href="#rid128">128</a>].</p><p></p><p class="headingAnchor" id="H2141612875"><span class="h2">Lynch syndrome</span><span class="headingEndMark"> — </span>Patients with Lynch syndrome (hereditary nonpolyposis colorectal cancer) are at risk for developing urothelial malignancies, especially those with mutations in mutS homolog 2 (<em>MSH2</em>) [<a href="#rid128">128</a>]. Upper tract urothelial carcinoma occurs in 5 percent of patients with Lynch syndrome, making it the third most common malignancy in this patient population. Patients with Lynch syndrome also have a lifetime risk of developing upper tract urothelial carcinoma of up to 20 percent [<a href="#rid129">129</a>].</p><p>The approach to screening patients with Lynch syndrome for urinary tract cancers is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/15804.html" rel="external">"Lynch syndrome (hereditary nonpolyposis colorectal cancer): Cancer screening and management", section on 'Urinary tract cancer'</a>.)</p><p class="headingAnchor" id="H30"><span class="h2">Oncogene and tumor suppressor genes</span><span class="headingEndMark"> — </span>A number of oncogenes and tumor suppressor genes may play a role in the pathogenesis of bladder cancer.</p><p class="bulletIndent1"><span class="glyph">●</span>The p53 tumor suppressor gene expresses a transcription factor that regulates the cell cycle. Over one-half of bladder tumors contain a mutation in the TP53 gene [<a href="#rid22">22,130,131</a>]. However, there is significant discordance between mutations in the p53 gene and protein alterations detectable by immunohistochemistry. A meta-analysis of 168 studies assessing the prognostic value of p53 overexpression showed a significant, although weak, association with the overall risk of recurrence and mortality [<a href="#rid132">132</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The retinoblastoma gene (<em>RB</em>) encodes a nuclear phosphoprotein that indirectly controls the cell division process. Alterations of the <em>RB</em> gene have been associated with bladder cancer progression [<a href="#rid130">130,133-137</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other genes that may be involved in the initiation of bladder cancer or its subsequent progression include p16 [<a href="#rid138">138-140</a>], matrix metalloproteinases [<a href="#rid141">141</a>], and genes involved in folate metabolism (methylene-tetrahydrofolate reductase and methionine synthase) [<a href="#rid142">142,143</a>].</p><p></p><p class="headingAnchor" id="H31"><span class="h2">Activation of carcinogens</span><span class="headingEndMark"> — </span>Most arylamines require in vivo activation to acquire carcinogenic potential, and several metabolic pathways have been identified. Genetic factors that regulate these metabolic steps may serve to modify the risk of developing bladder cancer after occupational or environmental exposure [<a href="#rid144">144</a>].</p><p>As an example, a series of P450 cytochrome enzymes (CYP1A2, CYP2D6, and CYP3A4) are involved in N-oxidation to N-hydroxylated metabolites, the initial step of arylamine activation. These enzymes are polymorphic in the general population, meaning that there are variants with slightly different molecular structures and biologic activities. High levels of enzymatic activity may facilitate the formation of activated arylamine metabolites and predispose to bladder carcinogenesis [<a href="#rid145">145-148</a>].</p><p>Case-control studies suggest that cigarette smokers with a genotype consistent with extensive metabolic activators have a significantly higher incidence of bladder cancer compared with controls [<a href="#rid149">149</a>].</p><p class="headingAnchor" id="H32"><span class="h2">Detoxification of carcinogens</span><span class="headingEndMark"> — </span>Differences in the endogenous mechanisms responsible for metabolizing chemical carcinogens may contribute to an altered risk of bladder cancer in response to such agents.</p><p>Acetylation can detoxify aromatic amines, which are known bladder cancer carcinogens. There are two known N-acetyltransferase genes (NAT1 and NAT2), which are important acetylating enzymes. The NAT2 enzyme is polymorphic and variations in the activity of NAT2 have been implicated as risk factors in the pathogenesis of bladder cancer [<a href="#rid150">150</a>]. Two normal NAT2 alleles allow for rapid acetylation and "fast" deactivation of carcinogens. By contrast, "slow" acetylators, who have two altered NAT2 alleles, appear to be at increased risk for bladder cancer when exposed to cigarette smoke or occupational aromatic amines [<a href="#rid151">151</a>]. (See <a class="local">'Cigarette smoke'</a> above and <a class="local">'Occupational carcinogen exposure'</a> above.)</p><p>A meta-analysis of 22 case-control studies found an increased risk of bladder cancer among NAT2 slow acetylators compared with rapid acetylators (relative risk 1.4, 95% CI 1.2-1.6). Using the predominantly male European study population and assuming a 2.5-fold increased risk of bladder cancer from smoking, the authors estimated that the population attributable risk was 35 percent for slow acetylators who had ever smoked and 13 percent for rapid acetylators who had ever smoked.</p><p>Another enzyme that may detoxify carcinogens in urine is glutathione S transferase M1 (GSTM1) [<a href="#rid152">152</a>]. Approximately half of White individuals in the United States have a deletion of both GSTM1 alleles with no enzymatic activity [<a href="#rid153">153</a>]. Epidemiologic data suggest that a deficiency of GSTM1 is also associated with an increased bladder cancer risk [<a href="#rid152">152,154</a>].</p><p>Further evidence in support of a role of both NAT2 and GSTM1 come from studies of genetic studies that have identified an increased risk of bladder cancer with polymorphisms in both of these genes [<a href="#rid155">155</a>].</p><p class="headingAnchor" id="H33"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology of urothelial carcinoma </strong>– Urothelial carcinoma of the bladder is the most frequent urinary tract malignancy, accounting for approximately 90 percent of bladder cancers in the United States and Western Europe. Urothelial cancer is approximately three times more common in males than females, and is primarily seen in older adults. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chemical carcinogenesis </strong>– Epidemiologic studies have identified various chemical carcinogens that are believed to be responsible for most cases of urothelial carcinoma. (See <a class="local">'Chemical carcinogenesis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cigarette smoke </strong>– Cigarette smoke is responsible for approximately one-half of cases of urothelial cancer in both males and females. (See <a class="local">'Cigarette smoke'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Opium </strong>– The use of opium has been associated with an increased risk of bladder cancer. (See <a class="local">'Opium'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Occupational carcinogen exposure </strong>– Occupational exposure to various chemical carcinogens is estimated to contribute approximately 20 percent of the bladder cancer burden. (See <a class="local">'Occupational carcinogen exposure'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetic effects </strong>– Genetic effects may play a direct role in the initiation and progression of urothelial carcinoma. (See <a class="local">'Genetic effects'</a> above.)</p><p></p><p class="bulletIndent1">Genetic factors may also modify the risk associated with exogenous agents, either through the activation or detoxification of potential carcinogens. (See <a class="local">'Activation of carcinogens'</a> above and <a class="local">'Detoxification of carcinogens'</a> above.)</p><p></p><p class="headingAnchor" id="H9434362"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Thomas M Becker, MD, PhD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Ploeg M, Aben KK, Kiemeney LA. The present and future burden of urinary bladder cancer in the world. World J Urol 2009; 27:289.</a></li><li><a class="nounderline abstract_t">Amin HAA, Kobaisi MH, Samir RM. Schistosomiasis and Bladder Cancer in Egypt: Truths and Myths. Open Access Maced J Med Sci 2019; 7:4023.</a></li><li class="breakAll">Global Cancer Observatory. International Agency for Research on Cancer. World Health Organization. Available at: https://gco.iarc.fr/ (Accessed on December 13, 2023).</li><li><a class="nounderline abstract_t">Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin 2024; 74:12.</a></li><li><a class="nounderline abstract_t">Marcos-Gragera R, Mallone S, Kiemeney LA, et al. Urinary tract cancer survival in Europe 1999-2007: Results of the population-based study EUROCARE-5. Eur J Cancer 2015.</a></li><li><a class="nounderline abstract_t">Pelucchi C, Bosetti C, Negri E, et al. Mechanisms of disease: The epidemiology of bladder cancer. Nat Clin Pract Urol 2006; 3:327.</a></li><li><a class="nounderline abstract_t">Feldman AR, Kessler L, Myers MH, Naughton MD. The prevalence of cancer. Estimates based on the Connecticut Tumor Registry. N Engl J Med 1986; 315:1394.</a></li><li><a class="nounderline abstract_t">Vercelli M, Quaglia A, Parodi S, Crosignani P. Cancer prevalence in the elderly. ITAPREVAL Working Group. Tumori 1999; 85:391.</a></li><li><a class="nounderline abstract_t">Wong MCS, Fung FDH, Leung C, et al. The global epidemiology of bladder cancer: a joinpoint regression analysis of its incidence and mortality trends and projection. Sci Rep 2018; 8:1129.</a></li><li><a class="nounderline abstract_t">Michaud DS, Clinton SK, Rimm EB, et al. Risk of bladder cancer by geographic region in a U.S. cohort of male health professionals. Epidemiology 2001; 12:719.</a></li><li><a class="nounderline abstract_t">Burger M, Catto JW, Dalbagni G, et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol 2013; 63:234.</a></li><li><a class="nounderline abstract_t">Lynch CF, Cohen MB. Urinary system. Cancer 1995; 75:316.</a></li><li><a class="nounderline abstract_t">Scosyrev E, Noyes K, Feng C, Messing E. Sex and racial differences in bladder cancer presentation and mortality in the US. Cancer 2009; 115:68.</a></li><li><a class="nounderline abstract_t">Hinotsu S, Akaza H, Miki T, et al. Bladder cancer develops 6 years earlier in current smokers: analysis of bladder cancer registry data collected by the cancer registration committee of the Japanese Urological Association. Int J Urol 2009; 16:64.</a></li><li><a class="nounderline abstract_t">Freedman ND, Abnet CC, Caporaso NE, et al. Impact of changing US cigarette smoking patterns on incident cancer: risks of 20 smoking-related cancers among the women and men of the NIH-AARP cohort. Int J Epidemiol 2016; 45:846.</a></li><li><a class="nounderline abstract_t">Linn JF, Sesterhenn I, Mostofi FK, Schoenberg M. The molecular characteristics of bladder cancer in young patients. J Urol 1998; 159:1493.</a></li><li><a class="nounderline abstract_t">Ryerson AB, Eheman CR, Altekruse SF, et al. Annual Report to the Nation on the Status of Cancer, 1975-2012, featuring the increasing incidence of liver cancer. Cancer 2016; 122:1312.</a></li><li><a class="nounderline abstract_t">Schulz MR, Loomis D. Occupational bladder cancer mortality among racial and ethnic minorities in 21 states. Am J Ind Med 2000; 38:90.</a></li><li><a class="nounderline abstract_t">Rabbani F, Perrotti M, Russo P, Herr HW. Upper-tract tumors after an initial diagnosis of bladder cancer: argument for long-term surveillance. J Clin Oncol 2001; 19:94.</a></li><li><a class="nounderline abstract_t">Kang CH, Yu TJ, Hsieh HH, et al. The development of bladder tumors and contralateral upper urinary tract tumors after primary transitional cell carcinoma of the upper urinary tract. Cancer 2003; 98:1620.</a></li><li><a class="nounderline abstract_t">Jones TD, Wang M, Eble JN, et al. Molecular evidence supporting field effect in urothelial carcinogenesis. Clin Cancer Res 2005; 11:6512.</a></li><li><a class="nounderline abstract_t">Hartmann A, Schlake G, Zaak D, et al. Occurrence of chromosome 9 and p53 alterations in multifocal dysplasia and carcinoma in situ of human urinary bladder. Cancer Res 2002; 62:809.</a></li><li><a class="nounderline abstract_t">Hafner C, Knuechel R, Stoehr R, Hartmann A. Clonality of multifocal urothelial carcinomas: 10 years of molecular genetic studies. Int J Cancer 2002; 101:1.</a></li><li><a class="nounderline abstract_t">Sidransky D, Frost P, Von Eschenbach A, et al. Clonal origin of bladder cancer. N Engl J Med 1992; 326:737.</a></li><li><a class="nounderline abstract_t">Louhelainen J, Wijkström H, Hemminki K. Allelic losses demonstrate monoclonality of multifocal bladder tumors. Int J Cancer 2000; 87:522.</a></li><li><a class="nounderline abstract_t">Kogevinas M, 't Mannetje A, Cordier S, et al. Occupation and bladder cancer among men in Western Europe. Cancer Causes Control 2003; 14:907.</a></li><li><a class="nounderline abstract_t">Vineis P, Pirastu R. Aromatic amines and cancer. Cancer Causes Control 1997; 8:346.</a></li><li><a class="nounderline abstract_t">Steineck G, Plato N, Norell SE, Hogstedt C. Urothelial cancer and some industry-related chemicals: an evaluation of the epidemiologic literature. Am J Ind Med 1990; 17:371.</a></li><li><a class="nounderline abstract_t">Freedman ND, Silverman DT, Hollenbeck AR, et al. Association between smoking and risk of bladder cancer among men and women. JAMA 2011; 306:737.</a></li><li><a class="nounderline abstract_t">Cumberbatch MG, Rota M, Catto JW, La Vecchia C. The Role of Tobacco Smoke in Bladder and Kidney Carcinogenesis: A Comparison of Exposures and Meta-analysis of Incidence and Mortality Risks. Eur Urol 2016; 70:458.</a></li><li><a class="nounderline abstract_t">Jubber I, Ong S, Bukavina L, et al. Epidemiology of Bladder Cancer in 2023: A Systematic Review of Risk Factors. Eur Urol 2023; 84:176.</a></li><li><a class="nounderline abstract_t">Hoffman D, Masuda Y, Wynder EL. Alpha-naphthylamine and beta-naphthylamine in cigarette smoke. Nature 1969; 221:255.</a></li><li><a class="nounderline abstract_t">Hecht SS. Cigarette smoking: cancer risks, carcinogens, and mechanisms. Langenbecks Arch Surg 2006; 391:603.</a></li><li><a class="nounderline abstract_t">Brennan P, Bogillot O, Cordier S, et al. Cigarette smoking and bladder cancer in men: a pooled analysis of 11 case-control studies. Int J Cancer 2000; 86:289.</a></li><li><a class="nounderline abstract_t">Brennan P, Bogillot O, Greiser E, et al. The contribution of cigarette smoking to bladder cancer in women (pooled European data). Cancer Causes Control 2001; 12:411.</a></li><li><a class="nounderline abstract_t">Pietzak EJ, Mucksavage P, Guzzo TJ, Malkowicz SB. Heavy Cigarette Smoking and Aggressive Bladder Cancer at Initial Presentation. Urology 2015; 86:968.</a></li><li><a class="nounderline abstract_t">Cacciamani GE, Ghodoussipour S, Mari A, et al. Association between Smoking Exposure, Neoadjuvant Chemotherapy Response and Survival Outcomes following Radical Cystectomy: Systematic Review and Meta-Analysis. J Urol 2020; 204:649.</a></li><li><a class="nounderline abstract_t">Chen CH, Shun CT, Huang KH, et al. Stopping smoking might reduce tumour recurrence in nonmuscle-invasive bladder cancer. BJU Int 2007; 100:281.</a></li><li><a class="nounderline abstract_t">Skipper PL, Tannenbaum SR, Ross RK, Yu MC. Nonsmoking-related arylamine exposure and bladder cancer risk. Cancer Epidemiol Biomarkers Prev 2003; 12:503.</a></li><li><a class="nounderline abstract_t">Jiang X, Yuan JM, Skipper PL, et al. Environmental tobacco smoke and bladder cancer risk in never smokers of Los Angeles County. Cancer Res 2007; 67:7540.</a></li><li><a class="nounderline abstract_t">Thomas AA, Wallner LP, Quinn VP, et al. Association between cannabis use and the risk of bladder cancer: results from the California Men's Health Study. Urology 2015; 85:388.</a></li><li><a class="nounderline abstract_t">IARC Monographs Vol 126 group. Carcinogenicity of opium consumption. Lancet Oncol 2020; 21:1407.</a></li><li><a class="nounderline abstract_t">Sheikh M, Shakeri R, Poustchi H, et al. Opium use and subsequent incidence of cancer: results from the Golestan Cohort Study. Lancet Glob Health 2020; 8:e649.</a></li><li><a class="nounderline abstract_t">Afshari M, Janbabaei G, Bahrami MA, Moosazadeh M. Opium and bladder cancer: A systematic review and meta-analysis of the odds ratios for opium use and the risk of bladder cancer. PLoS One 2017; 12:e0178527.</a></li><li><a class="nounderline abstract_t">Jung I, Messing E. Molecular mechanisms and pathways in bladder cancer development and progression. Cancer Control 2000; 7:325.</a></li><li><a class="nounderline abstract_t">Cole P, Hoover R, Friedell GH. Occupation and cancer of the lower urinary tract. Cancer 1972; 29:1250.</a></li><li><a class="nounderline abstract_t">CASE RA, HOSKER ME, McDONALD DB, PEARSON JT. Tumours of the urinary bladder in workmen engaged in the manufacture and use of certain dyestuff intermediates in the British chemical industry. I. The role of aniline, benzidine, alpha-naphthylamine, and beta-naphthylamine. Br J Ind Med 1954; 11:75.</a></li><li><a class="nounderline abstract_t">Pira E, Piolatto G, Negri E, et al. Bladder cancer mortality of workers exposed to aromatic amines: a 58-year follow-up. J Natl Cancer Inst 2010; 102:1096.</a></li><li><a class="nounderline abstract_t">Gaertner RR, Trpeski L, Johnson KC, Canadian Cancer Registries Epidemiology Research Group. A case-control study of occupational risk factors for bladder cancer in Canada. Cancer Causes Control 2004; 15:1007.</a></li><li><a class="nounderline abstract_t">Smailyte G, Kurtinaitis J, Andersen A. Mortality and cancer incidence among Lithuanian cement producing workers. Occup Environ Med 2004; 61:529.</a></li><li><a class="nounderline abstract_t">Zeegers MP, Swaen GM, Kant I, et al. Occupational risk factors for male bladder cancer: results from a population based case cohort study in the Netherlands. Occup Environ Med 2001; 58:590.</a></li><li><a class="nounderline abstract_t">Boffetta P, Dosemeci M, Gridley G, et al. Occupational exposure to diesel engine emissions and risk of cancer in Swedish men and women. Cancer Causes Control 2001; 12:365.</a></li><li><a class="nounderline abstract_t">Ma F, Fleming LE, Lee DJ, et al. Mortality in Florida professional firefighters, 1972 to 1999. Am J Ind Med 2005; 47:509.</a></li><li><a class="nounderline abstract_t">Youakim S. Risk of cancer among firefighters: a quantitative review of selected malignancies. Arch Environ Occup Health 2006; 61:223.</a></li><li><a class="nounderline abstract_t">LeMasters GK, Genaidy AM, Succop P, et al. Cancer risk among firefighters: a review and meta-analysis of 32 studies. J Occup Environ Med 2006; 48:1189.</a></li><li><a class="nounderline abstract_t">Haas NS, Gochfeld M, Robson MG, Wartenberg D. Latent health effects in firefighters. Int J Occup Environ Health 2003; 9:95.</a></li><li><a class="nounderline abstract_t">Ames BN, Kammen HO, Yamasaki E. Hair dyes are mutagenic: identification of a variety of mutagenic ingredients. Proc Natl Acad Sci U S A 1975; 72:2423.</a></li><li><a class="nounderline abstract_t">Henley SJ, Thun MJ. Use of permanent hair dyes and bladder-cancer risk. Int J Cancer 2001; 94:903.</a></li><li><a class="nounderline abstract_t">Hartge P, Hoover R, Altman R, et al. Use of hair dyes and risk of bladder cancer. Cancer Res 1982; 42:4784.</a></li><li><a class="nounderline abstract_t">Czene K, Tiikkaja S, Hemminki K. Cancer risks in hairdressers: assessment of carcinogenicity of hair dyes and gels. Int J Cancer 2003; 105:108.</a></li><li><a class="nounderline abstract_t">La Vecchia C, Tavani A. Hair dyes and bladder cancer: an update. Eur J Cancer Prev 2001; 10:205.</a></li><li><a class="nounderline abstract_t">Gago-Dominguez M, Castelao JE, Yuan JM, et al. Use of permanent hair dyes and bladder-cancer risk. Int J Cancer 2001; 91:575.</a></li><li><a class="nounderline abstract_t">Villanueva CM, Fernández F, Malats N, et al. Meta-analysis of studies on individual consumption of chlorinated drinking water and bladder cancer. J Epidemiol Community Health 2003; 57:166.</a></li><li><a class="nounderline abstract_t">Morris RD, Audet AM, Angelillo IF, et al. Chlorination, chlorination by-products, and cancer: a meta-analysis. Am J Public Health 1992; 82:955.</a></li><li><a class="nounderline abstract_t">Cantor KP, Lynch CF, Hildesheim ME, et al. Drinking water source and chlorination byproducts. I. Risk of bladder cancer. Epidemiology 1998; 9:21.</a></li><li><a class="nounderline abstract_t">Chevrier C, Junod B, Cordier S. Does ozonation of drinking water reduce the risk of bladder cancer? Epidemiology 2004; 15:605.</a></li><li><a class="nounderline abstract_t">Marshall G, Ferreccio C, Yuan Y, et al. Fifty-year study of lung and bladder cancer mortality in Chile related to arsenic in drinking water. J Natl Cancer Inst 2007; 99:920.</a></li><li><a class="nounderline abstract_t">Tsai SM, Wang TN, Ko YC. Cancer mortality trends in a blackfoot disease endemic community of Taiwan following water source replacement. J Toxicol Environ Health A 1998; 55:389.</a></li><li><a class="nounderline abstract_t">Smith AH, Marshall G, Roh T, et al. Lung, Bladder, and Kidney Cancer Mortality 40 Years After Arsenic Exposure Reduction. J Natl Cancer Inst 2018; 110:241.</a></li><li><a class="nounderline abstract_t">Moore LE, Smith AH, Eng C, et al. Arsenic-related chromosomal alterations in bladder cancer. J Natl Cancer Inst 2002; 94:1688.</a></li><li><a class="nounderline abstract_t">Chen CH, Chiou HY, Hsueh YM, et al. Clinicopathological characteristics and survival outcome of arsenic related bladder cancer in taiwan. J Urol 2009; 181:547.</a></li><li><a class="nounderline abstract_t">Mink PJ, Alexander DD, Barraj LM, et al. Low-level arsenic exposure in drinking water and bladder cancer: a review and meta-analysis. Regul Toxicol Pharmacol 2008; 52:299.</a></li><li><a class="nounderline abstract_t">Michaud DS, Spiegelman D, Clinton SK, et al. Fluid intake and the risk of bladder cancer in men. N Engl J Med 1999; 340:1390.</a></li><li><a class="nounderline abstract_t">Silverman DT, Alguacil J, Rothman N, et al. Does increased urination frequency protect against bladder cancer? Int J Cancer 2008; 123:1644.</a></li><li><a class="nounderline abstract_t">Lai MN, Wang SM, Chen PC, et al. Population-based case-control study of Chinese herbal products containing aristolochic acid and urinary tract cancer risk. J Natl Cancer Inst 2010; 102:179.</a></li><li><a class="nounderline abstract_t">Bejany DE, Lockhart JL, Rhamy RK. Malignant vesical tumors following spinal cord injury. J Urol 1987; 138:1390.</a></li><li><a class="nounderline abstract_t">Delnay KM, Stonehill WH, Goldman H, et al. Bladder histological changes associated with chronic indwelling urinary catheter. J Urol 1999; 161:1106.</a></li><li><a class="nounderline abstract_t">Groah SL, Weitzenkamp DA, Lammertse DP, et al. Excess risk of bladder cancer in spinal cord injury: evidence for an association between indwelling catheter use and bladder cancer. Arch Phys Med Rehabil 2002; 83:346.</a></li><li><a class="nounderline abstract_t">Michaud DS, Platz EA, Giovannucci E. Gonorrhoea and male bladder cancer in a prospective study. Br J Cancer 2007; 96:169.</a></li><li><a class="nounderline abstract_t">Matanoski GM, Elliott EA. Bladder cancer epidemiology. Epidemiol Rev 1981; 3:203.</a></li><li><a class="nounderline abstract_t">Magee PN, Barnes JM. Carcinogenic nitroso compounds. Adv Cancer Res 1967; 10:163.</a></li><li><a class="nounderline abstract_t">Schoppmann SF, Birner P, Stöckl J, et al. Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis. Am J Pathol 2002; 161:947.</a></li><li><a class="nounderline abstract_t">Nathan C. Points of control in inflammation. Nature 2002; 420:846.</a></li><li><a class="nounderline abstract_t">Murata M. Inflammation and cancer. Environ Health Prev Med 2018; 23:50.</a></li><li><a class="nounderline abstract_t">Leibovici D, Grossman HB, Dinney CP, et al. Polymorphisms in inflammation genes and bladder cancer: from initiation to recurrence, progression, and survival. J Clin Oncol 2005; 23:5746.</a></li><li><a class="nounderline abstract_t">Kawanishi S, Ohnishi S, Ma N, et al. Nitrative and oxidative DNA damage in infection-related carcinogenesis in relation to cancer stem cells. Genes Environ 2016; 38:26.</a></li><li><a class="nounderline abstract_t">Li N, Yang L, Zhang Y, et al. Human papillomavirus infection and bladder cancer risk: a meta-analysis. J Infect Dis 2011; 204:217.</a></li><li><a class="nounderline abstract_t">Raman JD, Sosa RE, Vaughan ED Jr, Scherr DS. Pathologic features of bladder tumors after nephroureterectomy or segmental ureterectomy for upper urinary tract transitional cell carcinoma. Urology 2007; 69:251.</a></li><li><a class="nounderline abstract_t">Matsui Y, Utsunomiya N, Ichioka K, et al. Risk factors for subsequent development of bladder cancer after primary transitional cell carcinoma of the upper urinary tract. Urology 2005; 65:279.</a></li><li><a class="nounderline abstract_t">Castellan M, Gosalbez R, Perez-Brayfield M, et al. Tumor in bladder reservoir after gastrocystoplasty. J Urol 2007; 178:1771.</a></li><li><a class="nounderline abstract_t">Soergel TM, Cain MP, Misseri R, et al. Transitional cell carcinoma of the bladder following augmentation cystoplasty for the neuropathic bladder. J Urol 2004; 172:1649.</a></li><li><a class="nounderline abstract_t">Shaw J, Lewis MA. Bladder augmentation surgery--what about the malignant risk? Eur J Pediatr Surg 1999; 9 Suppl 1:39.</a></li><li><a class="nounderline abstract_t">Vemulakonda VM, Lendvay TS, Shnorhavorian M, et al. Metastatic adenocarcinoma after augmentation gastrocystoplasty. J Urol 2008; 179:1094.</a></li><li><a class="nounderline abstract_t">Baydar DE, Allan RW, Castellan M, et al. Anaplastic signet ring cell carcinoma arising in gastrocystoplasty. Urology 2005; 65:1226.</a></li><li><a class="nounderline abstract_t">Kleinerman RA, Boice JD Jr, Storm HH, et al. Second primary cancer after treatment for cervical cancer. An international cancer registries study. Cancer 1995; 76:442.</a></li><li><a class="nounderline abstract_t">Travis LB, Curtis RE, Storm H, et al. Risk of second malignant neoplasms among long-term survivors of testicular cancer. J Natl Cancer Inst 1997; 89:1429.</a></li><li><a class="nounderline abstract_t">Guo X, Liu M, Hou H, et al. Impact of prostate cancer radiotherapy on the biological behavior and specific mortality of subsequent bladder cancer. Int J Clin Oncol 2019; 24:957.</a></li><li><a class="nounderline abstract_t">Wallis CJ, Mahar AL, Choo R, et al. Second malignancies after radiotherapy for prostate cancer: systematic review and meta-analysis. BMJ 2016; 352:i851.</a></li><li><a class="nounderline abstract_t">Sandhu JS, Vickers AJ, Bochner B, et al. Clinical characteristics of bladder cancer in patients previously treated with radiation for prostate cancer. BJU Int 2006; 98:59.</a></li><li><a class="nounderline abstract_t">Bostrom PJ, Soloway MS, Manoharan M, et al. Bladder cancer after radiotherapy for prostate cancer: detailed analysis of pathological features and outcome after radical cystectomy. J Urol 2008; 179:91.</a></li><li><a class="nounderline abstract_t">Shah SK, Lui PD, Baldwin DD, Ruckle HC. Urothelial carcinoma after external beam radiation therapy for prostate cancer. J Urol 2006; 175:2063.</a></li><li><a class="nounderline abstract_t">Yee DS, Shariat SF, Lowrance WT, et al. Impact of previous radiotherapy for prostate cancer on clinical outcomes of patients with bladder cancer. J Urol 2010; 183:1751.</a></li><li><a class="nounderline abstract_t">Keehn A, Ludmir E, Taylor J, Rabbani F. Incidence of bladder cancer after radiation for prostate cancer as a function of time and radiation modality. World J Urol 2017; 35:713.</a></li><li><a class="nounderline abstract_t">Travis LB, Curtis RE, Glimelius B, et al. Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma. J Natl Cancer Inst 1995; 87:524.</a></li><li><a class="nounderline abstract_t">Talar-Williams C, Hijazi YM, Walther MM, et al. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med 1996; 124:477.</a></li><li><a class="nounderline abstract_t">O'Keane JC. Carcinoma of the urinary bladder after treatment with cyclophosphamide. N Engl J Med 1988; 319:871.</a></li><li><a class="nounderline abstract_t">Pedersen-Bjergaard J, Ersbøll J, Hansen VL, et al. Carcinoma of the urinary bladder after treatment with cyclophosphamide for non-Hodgkin's lymphoma. N Engl J Med 1988; 318:1028.</a></li><li><a class="nounderline abstract_t">Habs MR, Schmähl D. Prevention of urinary bladder tumors in cyclophosphamide-treated rats by additional medication with the uroprotectors sodium 2-mercaptoethane sulfonate (mesna) and disodium 2,2'-dithio-bis-ethane sulfonate (dimesna). Cancer 1983; 51:606.</a></li><li><a class="nounderline abstract_t">Piper JM, Tonascia J, Matanoski GM. Heavy phenacetin use and bladder cancer in women aged 20 to 49 years. N Engl J Med 1985; 313:292.</a></li><li><a class="nounderline abstract_t">Porpáczy P, Schramek P. Analgesic nephropathy and phenacetin-induced transitional cell carcinoma - analysis of 300 patients with long-term consumption of phenacetin-containing drugs. Eur Urol 1981; 7:349.</a></li><li><a class="nounderline abstract_t">Daugherty SE, Pfeiffer RM, Sigurdson AJ, et al. Nonsteroidal antiinflammatory drugs and bladder cancer: a pooled analysis. Am J Epidemiol 2011; 173:721.</a></li><li><a class="nounderline abstract_t">Genkinger JM, De Vivo I, Stampfer MJ, et al. Nonsteroidal antiinflammatory drug use and risk of bladder cancer in the health professionals follow-up study. Int J Cancer 2007; 120:2221.</a></li><li><a class="nounderline abstract_t">Castaño-Vinyals G, Cantor KP, Malats N, et al. Air pollution and risk of urinary bladder cancer in a case-control study in Spain. Occup Environ Med 2008; 65:56.</a></li><li><a class="nounderline abstract_t">Soll-Johanning H, Bach E. Occupational exposure to air pollution and cancer risk among Danish urban mail carriers. Int Arch Occup Environ Health 2004; 77:351.</a></li><li><a class="nounderline abstract_t">Sontag JM. Experimental identification of genitourinary carcinogens. Urol Clin North Am 1980; 7:803.</a></li><li><a class="nounderline abstract_t">Armstrong BK. Saccharin/cyclamates: epidemiological evidence. IARC Sci Publ 1985; :129.</a></li><li><a class="nounderline abstract_t">Morrison AS. Advances in the etiology of urothelial cancer. Urol Clin North Am 1984; 11:557.</a></li><li><a class="nounderline abstract_t">Zeegers MP, Tan FE, Goldbohm RA, van den Brandt PA. Are coffee and tea consumption associated with urinary tract cancer risk? A systematic review and meta-analysis. Int J Epidemiol 2001; 30:353.</a></li><li><a class="nounderline abstract_t">Sala M, Cordier S, Chang-Claude J, et al. Coffee consumption and bladder cancer in nonsmokers: a pooled analysis of case-control studies in European countries. Cancer Causes Control 2000; 11:925.</a></li><li><a class="nounderline abstract_t">Zeegers MP, Dorant E, Goldbohm RA, van den Brandt PA. Are coffee, tea, and total fluid consumption associated with bladder cancer risk? Results from the Netherlands Cohort Study. Cancer Causes Control 2001; 12:231.</a></li><li><a class="nounderline abstract_t">Yu EYW, Dai Y, Wesselius A, et al. Coffee consumption and risk of bladder cancer: a pooled analysis of 501,604 participants from 12 cohort studies in the BLadder Cancer Epidemiology and Nutritional Determinants (BLEND) international study. Eur J Epidemiol 2020; 35:523.</a></li><li><a class="nounderline abstract_t">Takkouche B, Etminan M, Montes-Martínez A. Personal use of hair dyes and risk of cancer: a meta-analysis. JAMA 2005; 293:2516.</a></li><li><a class="nounderline abstract_t">Kogevinas M, Fernandez F, Garcia-Closas M, et al. Hair dye use is not associated with risk for bladder cancer: evidence from a case-control study in Spain. Eur J Cancer 2006; 42:1448.</a></li><li><a class="nounderline abstract_t">Plna K, Hemminki K. Familial bladder cancer in the National Swedish Family Cancer Database. J Urol 2001; 166:2129.</a></li><li><a class="nounderline abstract_t">Lin J, Spitz MR, Dinney CP, et al. Bladder cancer risk as modified by family history and smoking. Cancer 2006; 107:705.</a></li><li><a class="nounderline abstract_t">Martin C, Leiser CL, O'Neil B, et al. Familial Cancer Clustering in Urothelial Cancer: A Population-Based Case-Control Study. J Natl Cancer Inst 2018; 110:527.</a></li><li><a class="nounderline abstract_t">Murta-Nascimento C, Silverman DT, Kogevinas M, et al. Risk of bladder cancer associated with family history of cancer: do low-penetrance polymorphisms account for the increase in risk? Cancer Epidemiol Biomarkers Prev 2007; 16:1595.</a></li><li><a class="nounderline abstract_t">Carlo MI, Ravichandran V, Srinavasan P, et al. Cancer Susceptibility Mutations in Patients With Urothelial Malignancies. J Clin Oncol 2020; 38:406.</a></li><li><a class="nounderline abstract_t">Harper HL, McKenney JK, Heald B, et al. Upper tract urothelial carcinomas: frequency of association with mismatch repair protein loss and lynch syndrome. Mod Pathol 2017; 30:146.</a></li><li><a class="nounderline abstract_t">Shariat SF, Tokunaga H, Zhou J, et al. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. J Clin Oncol 2004; 22:1014.</a></li><li><a class="nounderline abstract_t">Sidransky D, Von Eschenbach A, Tsai YC, et al. Identification of p53 gene mutations in bladder cancers and urine samples. Science 1991; 252:706.</a></li><li><a class="nounderline abstract_t">Malats N, Bustos A, Nascimento CM, et al. P53 as a prognostic marker for bladder cancer: a meta-analysis and review. Lancet Oncol 2005; 6:678.</a></li><li><a class="nounderline abstract_t">Cote RJ, Dunn MD, Chatterjee SJ, et al. Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53. Cancer Res 1998; 58:1090.</a></li><li><a class="nounderline abstract_t">Cordon-Cardo C, Wartinger D, Petrylak D, et al. Altered expression of the retinoblastoma gene product: prognostic indicator in bladder cancer. J Natl Cancer Inst 1992; 84:1251.</a></li><li><a class="nounderline abstract_t">Grossman HB, Liebert M, Antelo M, et al. p53 and RB expression predict progression in T1 bladder cancer. Clin Cancer Res 1998; 4:829.</a></li><li><a class="nounderline abstract_t">Lipponen PK, Liukkonen TJ. Reduced expression of retinoblastoma (Rb) gene protein is related to cell proliferation and prognosis in transitional-cell bladder cancer. J Cancer Res Clin Oncol 1995; 121:44.</a></li><li><a class="nounderline abstract_t">Quentin T, Henke C, Korabiowska M, et al. Altered mRNA expression of the Rb and p16 tumor suppressor genes and of CDK4 in transitional cell carcinomas of the urinary bladder associated with tumor progression. Anticancer Res 2004; 24:1011.</a></li><li><a class="nounderline abstract_t">Li L, Yang T, Lian X. Effects of exogenous wild-type P16 gene transfection on the expression of cell cycle-related proteins in bladder cancer cell line. Cancer Invest 2005; 23:309.</a></li><li><a class="nounderline abstract_t">Benedict WF, Lerner SP, Zhou J, et al. Level of retinoblastoma protein expression correlates with p16 (MTS-1/INK4A/CDKN2) status in bladder cancer. Oncogene 1999; 18:1197.</a></li><li><a class="nounderline abstract_t">Friedrich MG, Blind C, Milde-Langosch K, et al. Frequent p16/MTS1 inactivation in early stages of urothelial carcinoma of the bladder is not associated with tumor recurrence. Eur Urol 2001; 40:518.</a></li><li><a class="nounderline abstract_t">Kader AK, Shao L, Dinney CP, et al. Matrix metalloproteinase polymorphisms and bladder cancer risk. Cancer Res 2006; 66:11644.</a></li><li><a class="nounderline abstract_t">Lin J, Spitz MR, Wang Y, et al. Polymorphisms of folate metabolic genes and susceptibility to bladder cancer: a case-control study. Carcinogenesis 2004; 25:1639.</a></li><li><a class="nounderline abstract_t">Papathoma AS, Petraki C, Grigorakis A, et al. Prognostic significance of matrix metalloproteinases 2 and 9 in bladder cancer. Anticancer Res 2000; 20:2009.</a></li><li><a class="nounderline abstract_t">Mommsen S, Aagaard J, Sell A. An epidemiological case-control study of bladder cancer in males from a predominantly rural district. Eur J Cancer Clin Oncol 1982; 18:1205.</a></li><li><a class="nounderline abstract_t">Branch RA, Chern HD, Adedoyin A, et al. The procarcinogen hypothesis for bladder cancer: activities of individual drug metabolizing enzymes as risk factors. Pharmacogenetics 1995; 5 Spec No:S97.</a></li><li><a class="nounderline abstract_t">Butler MA, Iwasaki M, Guengerich FP, Kadlubar FF. Human cytochrome P-450PA (P-450IA2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. Proc Natl Acad Sci U S A 1989; 86:7696.</a></li><li><a class="nounderline abstract_t">Kaisary A, Smith P, Jaczq E, et al. Genetic predisposition to bladder cancer: ability to hydroxylate debrisoquine and mephenytoin as risk factors. Cancer Res 1987; 47:5488.</a></li><li><a class="nounderline abstract_t">Bryant MS, Vineis P, Skipper PL, Tannenbaum SR. Hemoglobin adducts of aromatic amines: associations with smoking status and type of tobacco. Proc Natl Acad Sci U S A 1988; 85:9788.</a></li><li><a class="nounderline abstract_t">Kaderlik KR, Kadlubar FF. Metabolic polymorphisms and carcinogen-DNA adduct formation in human populations. Pharmacogenetics 1995; 5 Spec No:S108.</a></li><li><a class="nounderline abstract_t">Hein DW. N-acetyltransferase 2 genetic polymorphism: effects of carcinogen and haplotype on urinary bladder cancer risk. Oncogene 2006; 25:1649.</a></li><li><a class="nounderline abstract_t">Okkels H, Sigsgaard T, Wolf H, Autrup H. Arylamine N-acetyltransferase 1 (NAT1) and 2 (NAT2) polymorphisms in susceptibility to bladder cancer: the influence of smoking. Cancer Epidemiol Biomarkers Prev 1997; 6:225.</a></li><li><a class="nounderline abstract_t">Bell DA, Taylor JA, Paulson DF, et al. Genetic risk and carcinogen exposure: a common inherited defect of the carcinogen-metabolism gene glutathione S-transferase M1 (GSTM1) that increases susceptibility to bladder cancer. J Natl Cancer Inst 1993; 85:1159.</a></li><li><a class="nounderline abstract_t">Yu MC, Ross RK, Chan KK, et al. Glutathione S-transferase M1 genotype affects aminobiphenyl-hemoglobin adduct levels in white, black and Asian smokers and nonsmokers. Cancer Epidemiol Biomarkers Prev 1995; 4:861.</a></li><li><a class="nounderline abstract_t">García-Closas M, Malats N, Silverman D, et al. NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses. Lancet 2005; 366:649.</a></li><li><a class="nounderline abstract_t">Dong LM, Potter JD, White E, et al. Genetic susceptibility to cancer: the role of polymorphisms in candidate genes. JAMA 2008; 299:2423.</a></li></ol></div><div id="topicVersionRevision">Topic 2957 Version 47.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19219610" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The present and future burden of urinary bladder cancer in the world.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32165946" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Schistosomiasis and Bladder Cancer in Egypt: Truths and Myths.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32165946" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Schistosomiasis and Bladder Cancer in Egypt: Truths and Myths.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/38230766" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Cancer statistics, 2024.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26421824" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Urinary tract cancer survival in Europe 1999-2007: Results of the population-based study EUROCARE-5.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16763645" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Mechanisms of disease: The epidemiology of bladder cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3773965" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : The prevalence of cancer. Estimates based on the Connecticut Tumor Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10665856" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Cancer prevalence in the elderly. ITAPREVAL Working Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29348548" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : The global epidemiology of bladder cancer: a joinpoint regression analysis of its incidence and mortality trends and projection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11679802" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Risk of bladder cancer by geographic region in a U.S. cohort of male health professionals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22877502" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Epidemiology and risk factors of urothelial bladder cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8001003" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Urinary system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19072984" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Sex and racial differences in bladder cancer presentation and mortality in the US.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19054170" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Bladder cancer develops 6 years earlier in current smokers: analysis of bladder cancer registry data collected by the cancer registration committee of the Japanese Urological Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26411408" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Impact of changing US cigarette smoking patterns on incident cancer: risks of 20 smoking-related cancers among the women and men of the NIH-AARP cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9554340" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : The molecular characteristics of bladder cancer in young patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26959385" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Annual Report to the Nation on the Status of Cancer, 1975-2012, featuring the increasing incidence of liver cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10861770" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Occupational bladder cancer mortality among racial and ethnic minorities in 21 states.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11134200" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Upper-tract tumors after an initial diagnosis of bladder cancer: argument for long-term surveillance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14534877" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : The development of bladder tumors and contralateral upper urinary tract tumors after primary transitional cell carcinoma of the upper urinary tract.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16166427" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Molecular evidence supporting field effect in urothelial carcinogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11830537" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Occurrence of chromosome 9 and p53 alterations in multifocal dysplasia and carcinoma in situ of human urinary bladder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12209580" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Clonality of multifocal urothelial carcinomas: 10 years of molecular genetic studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1445507" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Clonal origin of bladder cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10918192" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Allelic losses demonstrate monoclonality of multifocal bladder tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14750529" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Occupation and bladder cancer among men in Western Europe.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9498898" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Aromatic amines and cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2407118" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Urothelial cancer and some industry-related chemicals: an evaluation of the epidemiologic literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21846855" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Association between smoking and risk of bladder cancer among men and women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26149669" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : The Role of Tobacco Smoke in Bladder and Kidney Carcinogenesis: A Comparison of Exposures and Meta-analysis of Incidence and Mortality Risks.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37198015" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Epidemiology of Bladder Cancer in 2023: A Systematic Review of Risk Factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5763078" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Alpha-naphthylamine and beta-naphthylamine in cigarette smoke.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17031696" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Cigarette smoking: cancer risks, carcinogens, and mechanisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10738259" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Cigarette smoking and bladder cancer in men: a pooled analysis of 11 case-control studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11545456" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : The contribution of cigarette smoking to bladder cancer in women (pooled European data).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26190088" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Heavy Cigarette Smoking and Aggressive Bladder Cancer at Initial Presentation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32105187" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Association between Smoking Exposure, Neoadjuvant Chemotherapy Response and Survival Outcomes following Radical Cystectomy: Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17419696" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Stopping smoking might reduce tumour recurrence in nonmuscle-invasive bladder cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12814994" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Nonsmoking-related arylamine exposure and bladder cancer risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17671226" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Environmental tobacco smoke and bladder cancer risk in never smokers of Los Angeles County.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25623697" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Association between cannabis use and the risk of bladder cancer: results from the California Men's Health Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33038940" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Carcinogenicity of opium consumption.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32353313" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Opium use and subsequent incidence of cancer: results from the Golestan Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28586371" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Opium and bladder cancer: A systematic review and meta-analysis of the odds ratios for opium use and the risk of bladder cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10895126" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Molecular mechanisms and pathways in bladder cancer development and progression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5021618" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Occupation and cancer of the lower urinary tract.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13149741" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Tumours of the urinary bladder in workmen engaged in the manufacture and use of certain dyestuff intermediates in the British chemical industry. I. The role of aniline, benzidine, alpha-naphthylamine, and beta-naphthylamine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20548022" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Bladder cancer mortality of workers exposed to aromatic amines: a 58-year follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15801485" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : A case-control study of occupational risk factors for bladder cancer in Canada.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15150393" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Mortality and cancer incidence among Lithuanian cement producing workers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11511746" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Occupational risk factors for male bladder cancer: results from a population based case cohort study in the Netherlands.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11456233" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Occupational exposure to diesel engine emissions and risk of cancer in Swedish men and women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15898094" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Mortality in Florida professional firefighters, 1972 to 1999.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17891891" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Risk of cancer among firefighters: a quantitative review of selected malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17099456" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Cancer risk among firefighters: a review and meta-analysis of 32 studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12848236" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Latent health effects in firefighters.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1094469" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Hair dyes are mutagenic: identification of a variety of mutagenic ingredients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11745498" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Use of permanent hair dyes and bladder-cancer risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7127313" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Use of hair dyes and risk of bladder cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12672039" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Cancer risks in hairdressers: assessment of carcinogenicity of hair dyes and gels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11432706" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Hair dyes and bladder cancer: an update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11251984" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Use of permanent hair dyes and bladder-cancer risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12594192" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Meta-analysis of studies on individual consumption of chlorinated drinking water and bladder cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1535181" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Chlorination, chlorination by-products, and cancer: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9430264" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Drinking water source and chlorination byproducts. I. Risk of bladder cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15308961" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Does ozonation of drinking water reduce the risk of bladder cancer?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17565158" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Fifty-year study of lung and bladder cancer mortality in Chile related to arsenic in drinking water.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9833970" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Cancer mortality trends in a blackfoot disease endemic community of Taiwan following water source replacement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29069505" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Lung, Bladder, and Kidney Cancer Mortality 40 Years After Arsenic Exposure Reduction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12441324" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Arsenic-related chromosomal alterations in bladder cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19084863" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Clinicopathological characteristics and survival outcome of arsenic related bladder cancer in taiwan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18783726" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Low-level arsenic exposure in drinking water and bladder cancer: a review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10228189" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Fluid intake and the risk of bladder cancer in men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18623081" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Does increased urination frequency protect against bladder cancer?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20026811" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Population-based case-control study of Chinese herbal products containing aristolochic acid and urinary tract cancer risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3682066" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Malignant vesical tumors following spinal cord injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10081848" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Bladder histological changes associated with chronic indwelling urinary catheter.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11887115" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Excess risk of bladder cancer in spinal cord injury: evidence for an association between indwelling catheter use and bladder cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17164760" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Gonorrhoea and male bladder cancer in a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7030761" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Bladder cancer epidemiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4862936" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Carcinogenic nitroso compounds.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12213723" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12490957" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Points of control in inflammation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30340457" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Inflammation and cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16110031" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Polymorphisms in inflammation genes and bladder cancer: from initiation to recurrence, progression, and survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28050219" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Nitrative and oxidative DNA damage in infection-related carcinogenesis in relation to cancer stem cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21673031" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Human papillomavirus infection and bladder cancer risk: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17320658" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Pathologic features of bladder tumors after nephroureterectomy or segmental ureterectomy for upper urinary tract transitional cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15708038" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Risk factors for subsequent development of bladder cancer after primary transitional cell carcinoma of the upper urinary tract.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17707009" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Tumor in bladder reservoir after gastrocystoplasty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15371782" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Transitional cell carcinoma of the bladder following augmentation cystoplasty for the neuropathic bladder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10661792" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Bladder augmentation surgery--what about the malignant risk?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18206936" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Metastatic adenocarcinoma after augmentation gastrocystoplasty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15922432" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Anaplastic signet ring cell carcinoma arising in gastrocystoplasty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8625126" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Second primary cancer after treatment for cervical cancer. An international cancer registries study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9326912" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Risk of second malignant neoplasms among long-term survivors of testicular cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30903422" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Impact of prostate cancer radiotherapy on the biological behavior and specific mortality of subsequent bladder cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26936410" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Second malignancies after radiotherapy for prostate cancer: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16626308" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Clinical characteristics of bladder cancer in patients previously treated with radiation for prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17997457" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Bladder cancer after radiotherapy for prostate cancer: detailed analysis of pathological features and outcome after radical cystectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16697804" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Urothelial carcinoma after external beam radiation therapy for prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20299035" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Impact of previous radiotherapy for prostate cancer on clinical outcomes of patients with bladder cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27629559" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Incidence of bladder cancer after radiation for prostate cancer as a function of time and radiation modality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7707439" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8602705" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3412418" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Carcinoma of the urinary bladder after treatment with cyclophosphamide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3352696" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Carcinoma of the urinary bladder after treatment with cyclophosphamide for non-Hodgkin's lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6401591" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Prevention of urinary bladder tumors in cyclophosphamide-treated rats by additional medication with the uroprotectors sodium 2-mercaptoethane sulfonate (mesna) and disodium 2,2'-dithio-bis-ethane sulfonate (dimesna).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4010740" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Heavy phenacetin use and bladder cancer in women aged 20 to 49 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7286004" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Analgesic nephropathy and phenacetin-induced transitional cell carcinoma - analysis of 300 patients with long-term consumption of phenacetin-containing drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21367875" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Nonsteroidal antiinflammatory drugs and bladder cancer: a pooled analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17290403" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Nonsteroidal antiinflammatory drug use and risk of bladder cancer in the health professionals follow-up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17634245" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Air pollution and risk of urinary bladder cancer in a case-control study in Spain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15108001" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Occupational exposure to air pollution and cancer risk among Danish urban mail carriers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6779409" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Experimental identification of genitourinary carcinogens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2417949" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Saccharin/cyclamates: epidemiological evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6506370" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Advances in the etiology of urothelial cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11369742" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Are coffee and tea consumption associated with urinary tract cancer risk? A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11142527" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Coffee consumption and bladder cancer in nonsmokers: a pooled analysis of case-control studies in European countries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11405328" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Are coffee, tea, and total fluid consumption associated with bladder cancer risk? Results from the Netherlands Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31927701" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Coffee consumption and risk of bladder cancer: a pooled analysis of 501,604 participants from 12 cohort studies in the BLadder Cancer Epidemiology and Nutritional Determinants (BLEND) international study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15914752" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Personal use of hair dyes and risk of cancer: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16740387" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Hair dye use is not associated with risk for bladder cancer: evidence from a case-control study in Spain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11696721" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Familial bladder cancer in the National Swedish Family Cancer Database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16845665" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Bladder cancer risk as modified by family history and smoking.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29228305" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Familial Cancer Clustering in Urothelial Cancer: A Population-Based Case-Control Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17684133" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Risk of bladder cancer associated with family history of cancer: do low-penetrance polymorphisms account for the increase in risk?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31794323" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Cancer Susceptibility Mutations in Patients With Urothelial Malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27713421" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Upper tract urothelial carcinomas: frequency of association with mismatch repair protein loss and lynch syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14981102" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2024123" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Identification of p53 gene mutations in bladder cancers and urine samples.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16129368" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : P53 as a prognostic marker for bladder cancer: a meta-analysis and review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9515785" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1640484" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Altered expression of the retinoblastoma gene product: prognostic indicator in bladder cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9563875" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : p53 and RB expression predict progression in T1 bladder cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7860618" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Reduced expression of retinoblastoma (Rb) gene protein is related to cell proliferation and prognosis in transitional-cell bladder cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15161057" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Altered mRNA expression of the Rb and p16 tumor suppressor genes and of CDK4 in transitional cell carcinomas of the urinary bladder associated with tumor progression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16100943" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Effects of exogenous wild-type P16 gene transfection on the expression of cell cycle-related proteins in bladder cancer cell line.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10022125" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Level of retinoblastoma protein expression correlates with p16 (MTS-1/INK4A/CDKN2) status in bladder cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11752859" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Frequent p16/MTS1 inactivation in early stages of urothelial carcinoma of the bladder is not associated with tumor recurrence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17178858" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Matrix metalloproteinase polymorphisms and bladder cancer risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15117811" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Polymorphisms of folate metabolic genes and susceptibility to bladder cancer: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10928143" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Prognostic significance of matrix metalloproteinases 2 and 9 in bladder cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6897634" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : An epidemiological case-control study of bladder cancer in males from a predominantly rural district.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7581498" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : The procarcinogen hypothesis for bladder cancer: activities of individual drug metabolizing enzymes as risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2813353" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Human cytochrome P-450PA (P-450IA2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3652049" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Genetic predisposition to bladder cancer: ability to hydroxylate debrisoquine and mephenytoin as risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3200858" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : Hemoglobin adducts of aromatic amines: associations with smoking status and type of tobacco.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7581479" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : Metabolic polymorphisms and carcinogen-DNA adduct formation in human populations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16550165" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : N-acetyltransferase 2 genetic polymorphism: effects of carcinogen and haplotype on urinary bladder cancer risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9107426" id="rid150" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>151 : Arylamine N-acetyltransferase 1 (NAT1) and 2 (NAT2) polymorphisms in susceptibility to bladder cancer: the influence of smoking.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8320745" id="rid151" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>152 : Genetic risk and carcinogen exposure: a common inherited defect of the carcinogen-metabolism gene glutathione S-transferase M1 (GSTM1) that increases susceptibility to bladder cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8634658" id="rid152" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>153 : Glutathione S-transferase M1 genotype affects aminobiphenyl-hemoglobin adduct levels in white, black and Asian smokers and nonsmokers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16112301" id="rid153" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>154 : NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18505952" id="rid154" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>155 : Genetic susceptibility to cancer: the role of polymorphisms in candidate genes.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
